Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220384 | 1.00 | ADORA3 (0.69) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL31139492 | 1.00 | ADORA3 (0.69) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL1060584 | 0.92 | ADORA1 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL26370816 | 0.92 | ADORA1 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL29408565 | 0.92 | ADORA1 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL1060588 | 0.92 | ADORA1 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL28680450 | 0.92 | ADORA1 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL24264106 | 0.90 | ADORA1 (0.61) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL13777063 | 0.90 | ADORA3 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL21418864 | 0.89 | ADORA3 (0.75) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4495240-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-4495241-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023176862-A1 | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176863-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| CN-108424432-B | Preparation method of 3' -O-methoxyethyl nucleoside | 上海兆维科技发展有限公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-6653458-B1 | Phosphodiester or phosphorothioate internucleotide linkages at 2',5' positions; substituents at 3'; nuclease resistance and increased binding affinity; use as antisense agents | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6617442-B1 | Divided into two portions, one of which supports cleavage of target RNA; use in enhancing antisense therapies | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1180113-A4 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1180113-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066609-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | ADORA3 159/4885ADORA1 268/4885SMN1; SMN2 1822/4885 |
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | ADORA3 1318/4885ADORA1 1753/4885SMN1; SMN2 582/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | ADORA3 3807/4885ADORA1 4046/4885SMN1; SMN2 1617/4885 |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | ADORA3 159/4885ADORA1 268/4885SMN1; SMN2 1822/4885 |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | ADORA3 1033/4885ADORA1 1431/4885SMN1; SMN2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.